^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A single-arm, open, multicenter clinical trial to evaluate the efficacy and safety of HYML-122 tablets in combination with cytarabine in patients with relapsed or refractory FLT3 mutations
Excerpt:
...Subjects whose bone marrow or peripheral blood gene test is positive for FLT3 mutation, and the subject has any of the following FLT3 mutation types, can be selected: FLT3-ITD, FLT3-TKD/D835V, FLT3-TKD/D835H; 5. ...
Trial ID:
Source:
Title:
FIVE-YEAR REAL-WORLD DATA ON ACUTE MYELOID LEUKEMIA: RETROSPECTIVE STUDY FROM PUBLIC HEALTH CENTER IN BRAZIL
Published date:
05/11/2023
Excerpt:
To assess effectiveness (Eligible to the Next Treatment-ENT CR and suficient performance status to the nexttreatment, PFS and OS) and security (Early Mortality) of cytarabine and anthracycline (“7 + 3”regimen)….Subgroups analyzed were about FTL3 and NPM1 mutations....It was a retrospective analysis of all the cases of non-promyelocytic AML ....There were 21% and 11% patients with FLT3-ITD and NPM1 mutations, respectively....The median of PFS and OS were 3.6 and 8.2 months respectively. Patients with FLT3mutation, platelet < 20.000 and leukocytes < 10.000 had poor outcomes....Patients with FLT3 mutation, platelet < 20.000 and leukocytes < 10.000 had poor outcomes.
Secondary therapy:
Chemotherapy
